Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Alexander Eggermont
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Procedures
Disorders
Chemicals & Drugs
Anatomy
Living Beings
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
68
ten Hagen, Timo
58
de Wilt, Johannes
39
van Geel, Albertus
34
Kroon, Bin
27
Verhoef, Cornelis
26
van Tiel, Sandra
26
Kuppen, Peter
24
Kruit, Wim
22
Fleuren, Gert Jan
21
Klaase, Joost
19
van de Velde, Cornelis
18
Liénard, Danielle
17
Nieweg, Omgo
16
Seynhaeve, Ann
16
Vrouenraets, Bart
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Alexander Eggermont (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Eggermont Alexander M M
Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6745-7.
-
2009: van Akkooi Alexander C J; Spatz Alain; Eggermont Alexander M M; Mihm Martin; Cook Martin G
Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden.
European journal of cancer (Oxford, England : 1990) 2009;45(16):2736-42.
-
2009: Voit Christiane A; van Akkooi Alexander C J; Schäfer-Hesterberg Gregor; Schoengen Alfred; Schmitz Paul I M; Sterry Wolfram; Eggermont Alexander M M
Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4994-5000.
-
2009: Chakera Annette H; Hesse Birger; Burak Zeynep; Ballinger James R; Britten Allan; Caracò Corrado; Cochran Alistair J; Cook Martin G; Drzewiecki Krzysztof T; Essner Richard; Even-Sapir Einat; Eggermont Alexander M M; Stopar Tanja Gmeiner; Ingvar Christian; Mihm Martin C; McCarthy Stanley W; Mozzillo Nicola; Nieweg Omgo E; Scolyer Richard A; Starz Hans; Thompson John F; Trifirò Giuseppe; Viale Giuseppe; Vidal-Sicart Sergi; Uren Roger; Waddington Wendy; Chiti Arturo; Spatz Alain; Testori Alessandro
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.
European journal of nuclear medicine and molecular imaging 2009;36(10):1713-42.
-
2009: Fekkes Durk; Van Gool Arthur R; Bannink Marjolein; Sleijfer Stefan; Kruit Wim H J; van der Holt Bronno; Eggermont Alexander M M; Hengeveld Michiel W; Stoter Gerrit
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.
Amino acids 2009;37(4):703-8.
-
2009: Eggermont Alexander M M
Therapeutic vaccines in solid tumours: can they be harmful?
European journal of cancer (Oxford, England : 1990) 2009;45(12):2087-90.
-
2009: Agarwala Sanjiv S; Keilholz Ulrich; Gilles Erard; Bedikian Agop Y; Wu Jane; Kay Richard; Stein Cy A; Itri Loretta M; Suciu Stefan; Eggermont Alexander M M
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
European journal of cancer (Oxford, England : 1990) 2009;45(10):1807-14.
-
2009: Bouwhuis Marna G; Suciu Stefan; Collette Sandra; Aamdal Steinar; Kruit Wim H; Bastholt Lars; Stierner Ulrika; Salès François; Patel Poulam; Punt Cornelis J A; Hernberg Micaela; Spatz Alain; ten Hagen Timo L M; Hansson Johan; Eggermont Alexander M M;
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Journal of the National Cancer Institute 2009;101(12):869-77.
-
2009: Eggermont Alexander M M; Schadendorf Dirk
Melanoma and immunotherapy.
Hematology/oncology clinics of North America 2009;23(3):547-64, ix-x.
-
2009: Eggermont Alexander M M
Immunotherapy: Vaccine trials in melanoma -- time for reflection.
Nature reviews. Clinical oncology 2009;6(5):256-8.
-
2009: van der Pool Anne E M; Lalmahomed Z S; de Wilt Johannes H W; Eggermont Alexander M M; Ijzermans Jan M N; Verhoef Cornelis
Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2009;13(5):890-5.
-
2009: Verhoef Cornelis; van der Pool Anne E M; Nuyttens Joost J; Planting Andre S T; Eggermont Alexander M M; de Wilt Johannes H W
The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases.
Diseases of the colon and rectum 2009;52(1):23-30.
-
2009: Grünhagen Dirk J G; de Wilt Johannes H W; van Geel Albertus N; Verhoef Cornelis; Eggermont Alexander M M
Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2009;179():257-70.
-
2008: Voit Christiane A; Schäfer-Hesterberg Gregor; Kron Martina; van Akkooi Alexander C J; Rademaker Juergen; Lukowsky Ansgar; Schoengen Alfred; Schwürzer-Voit Markus; Sterry Wolfram; Krause Markus; Röwert-Huber Joachim; Eggermont Alexander M M
Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(35):5742-7.
-
2008: Van Gool Arthur R; Verkerk Robert; Fekkes Durk; Bannink Marjolein; Sleijfer Stefan; Kruit Wim H J; van der Holt Bronno; Scharpé Simon; Eggermont Alexander M M; Stoter Gerrit; Hengeveld Michiel W
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Psychiatry and clinical neurosciences 2008;62(5):597-602.
-
2008: Verhoef Cornelis; de Wilt Johannes H W; ten Hagen Timo L M; Eggermont Alexander M M
Isolated hepatic perfusion for the treatment of liver tumors: sunset or sunrise?
Surgical oncology clinics of North America 2008;17(4):877-94, xi.
-
2008: de Wilt Johannes H W; van Akkooi Alexander C J; Verhoef Cornelis; Eggermont Alexander M M
Detection of melanoma micrometastases in sentinel nodes - the cons.
Surgical oncology 2008;17(3):175-81.
-
2008: Eggermont Alexander M M; Suciu Stefan; Santinami Mario; Testori Alessandro; Kruit Wim H J; Marsden Jeremy; Punt Cornelis J A; Salès François; Gore Martin; Mackie Rona; Kusic Zvonko; Dummer Reinhard; Hauschild Axel; Musat Elena; Spatz Alain; Keilholz Ulrich;
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Lancet 2008;372(9633):117-26.
-
2008: Mearadji Amir; den Bakker Michael A; van Geel Albertus N; Eggermont Alexander M M; Sleijfer Stefan; Verweij Jaap; de Wilt Johannes H W; Verhoef Cornelis
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Anti-cancer drugs 2008;19(6):607-12.
-
2008: Eggermont Alexander M M; Voit Christiane
Management of melanoma: a European perspective.
Surgical oncology clinics of North America 2008;17(3):635-48, x.
-
2008: Vermaas Maarten; Nuyttens Joost J M E; Ferenschild Floris T J; Verhoef Cornelis; Eggermont Alexander M M; de Wilt Johannes H W
Reirradiation, surgery and IORT for recurrent rectal cancer in previously irradiated patients.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2008;87(3):357-60.
-
2008: de Wilt Johannes H W; Eggermont Alexander M M
When to perform surgery in stage IV melanoma patients?
Onkologie 2008;31(5):226-7.
-
2008: Ten Hagen Timo L M; Eggermont Alexander M M
Laboratory models of regional chemotherapy.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2008;24(3):291-9.
-
2008: Verhoef Cornelis; de Wilt Johannes H W; Brunstein Flavia; Marinelli Andreas W K S; van Etten Boudewijn; Vermaas Maarten; Guetens Gunther; de Boeck Gert; de Bruijn Ernst A; Eggermont Alexander M M
Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.
Annals of surgical oncology 2008;15(5):1367-74.
-
2008: van Akkooi Alexander C J; de Wilt Johannes H W; Voit Christiane; Verhoef Cees; Suciu Stefan; Eggermont Alexander M M
Sentinel lymph-node false positivity in melanoma.
Nature clinical practice. Oncology 2008;5(4):E2.
-
2008: ten Hagen Timo L M; Seynhaeve Ann L B; Eggermont Alexander M M
Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.
Immunological reviews 2008;222():299-315.
-
2008: Bannink Marjolein; Kruit Wim H J; Van Gool Arthur R; Sleijfer Stefan; van der Holt Bronno; Eggermont Alexander M M; Stoter Gerrit; Hengeveld Michiel W
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Psychosomatics 2008;49(1):56-63.
-
2008: Seynhaeve Ann L B; Eggermont Alexander M M; ten Hagen Timo L M
TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective".
Frontiers in bioscience : a journal and virtual library 2008;13():3034-45.
-
2007: Eggermont Alexander M M; Gore Martin
Randomized adjuvant therapy trials in melanoma: surgical and systemic.
Seminars in oncology 2007;34(6):509-15.
-
2007: Verhoef Cornelis; de Wilt Johannes H W; Grünhagen Dirk J; van Geel Albertus N; ten Hagen Timo L M; Eggermont Alexander M M
Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.
Current treatment options in oncology 2007;8(6):417-27.
-
2007: Seynhaeve Ann L B; Hoving Saske; Schipper Debby; Vermeulen Cindy E; de Wiel-Ambagtsheer Gisela aan; van Tiel Sandra T; Eggermont Alexander M M; Ten Hagen Timo L M
Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.
Cancer research 2007;67(19):9455-62.
-
2007: van Akkooi A C J; Bouwhuis M G; de Wilt J H W; Kliffen M; Schmitz P I M; Eggermont A M M
Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
The British journal of surgery 2007;94(10):1293-9.
-
2007: Vermaas M; Gosselink M P; Ferenschild F T J; van den Aardweg E; Lont H E; Kemperman H W P M; van der Harst E; Tetteroo G W M; Oostenbroek R J; Dijkhuis C M; Eggermont A M M; de Wilt J H W
Introduction of preoperative radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33(7):862-7.
-
2007: Menke-Plugmers M B E; Wai R Tjong Joe; van Geel A N; Eggermont A M M
[Oncoplastic surgery of the breast: a combination of oncological and plastic surgery]
Nederlands tijdschrift voor geneeskunde 2007;151(29):1623-7.
-
2007: van Geel Albertus N; den Bakker Michael A; Kirkels Wim; Horenblas Simon; Kroon Bin B R; de Wilt Johannes H W; Eggermont Alexander M M; Mooi Wolter J; van der Aa Madelon N A
Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature.
Urology 2007;70(1):143-7.
-
2007: Elliott Bruce; Scolyer Richard A; Suciu Stefan; Lebecque Serge; Rimoldi Donata; Gugerli Oliver; Musat Elena; Sharma Raghwa N; Lienard Danielle; Keilholz Ulrich; Testori Alessandro; Eggermont Alexander; MacKie Rona; Robert Caroline; Cook Martin; Thompson John F; Angevin Eric; Spatz Alain;
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3825-30.
-
2007: van Geel A N; van der Pol C; Notenboom A; Nuyttens J J; Eggermont A M M; Surmont V; Maat A P W M
[Long-term results of the multidisciplinary surgical treatment of non-small-cell bronchial carcinoma in the superior sulcus (Pancoast tumour): a retrospective study]
Nederlands tijdschrift voor geneeskunde 2007;151(25):1406-11.
-
2007: de Vries E; Houterman S; Janssen-Heijnen M L G; Nijsten T; van de Schans S A M; Eggermont A M M; Coebergh J W W
Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(6):1110-6.
-
2007: Vermaas M; Ferenschild F T J; Verhoef C; Nuyttens J J M E; Marinelli A W K S; Wiggers T; Kirkels W J; Eggermont A M M; de Wilt J H W
Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33(4):452-8.
-
2007: Schmidt Henrik; Suciu Stefan; Punt Cornelis J A; Gore Martin; Kruit Wim; Patel Poulam; Lienard Danielle; von der Maase Hans; Eggermont Alexander M M; Keilholz Ulrich;
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1562-9.
-
2007: Lejeune Ferdy J; Eggermont Alexander M M
Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(11):1449-50; author reply 1450-1.
-
2007: Brunstein Flavia; Hoving Saske; aan de Wiel-Ambagtsheer Gisela; de Bruijn Ernst A; Guetens Gunther; Eggermont Alexander M M; ten Hagen Timo L M
Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion.
Cancer immunology, immunotherapy : CII 2007;56(4):573-80.
-
2007: Brekelmans C T M; Tilanus-Linthorst M M A; Seynaeve C; vd Ouweland A; Menke-Pluymers M B E; Bartels C C M; Kriege M; van Geel A N; Burger C W; Eggermont A M M; Meijers-Heijboer H; Klijn J G M
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
European journal of cancer (Oxford, England : 1990) 2007;43(5):867-76.
-
2007: van Akkooi A C J; Bouwhuis M G; van Geel A N; Hoedemaker R; Verhoef C; Grunhagen D J; Schmitz P I M; Eggermont A M M; de Wilt J H W
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33(1):102-8.
-
2007: Brunstein Flavia; Eggermont Alexander M M; de Wiel-Ambagtsheer Gisela aan; van Tiel Sandra T; Rens Joost; ten Hagen Timo L M
Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.
Annals of surgical oncology 2007;14(2):795-801.
-
2007: Fekkes D; Bannink M; Kruit W H J; Van Gool A R; Mulder P G H; Sleijfer S; Eggermont A M M; Stoter G
Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients.
Amino acids 2007;32(1):121-6.
-
2007: Bannink Marjolein; Fekkes Durk; Van Gool Arthur R; Kruit Wim H J; Sleijfer Stefan; van der Holt Bronno; Eggermont Alexander M M; Stoter Gerrit; Hengeveld Michiel W
Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.
Neuropsychobiology 2007;55(3-4):225-31.
-
2006: Brunstein F; Rens J; van Tiel S T; Eggermont A M M; ten Hagen T L M
Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.
British journal of cancer 2006;95(12):1663-9.
-
2006: van Horssen Remco; Rens Joost A P; Schipper Debby; Eggermont Alexander M M; ten Hagen Timo L M
EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.
Apoptosis : an international journal on programmed cell death 2006;11(12):2137-45.
-
2006: Han-Geurts I J M; van Geel A N; van Doorn L; M den Bakker; Eggermont A M M; Verhoef C
Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(10):1217-21.
-
2006: van Horssen Remco; Galjart Niels; Rens Joost A P; Eggermont Alexander M M; ten Hagen Timo L M
Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay.
Journal of cellular biochemistry 2006;99(6):1536-52.
-
2006: Punt C J A; Suciu S; Gore M A; Koller J; Kruit W H J; Thomas J; Patel P; Lienard D; Eggermont A M M; Keilholz U
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2991-5.
-
2006: van Akkooi A C J; Verhoef C; van Geel A N; Kliffen M; Eggermont A M M; de Wilt J H W
Sentinel node biopsy for clear cell sarcoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(9):996-9.
-
2006: van Akkooi A C J; de Wilt J H W; Verhoef C; Schmitz P I M; van Geel A N; Eggermont A M M; Kliffen M
Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(10):1578-85.
-
2006: Eggermont Alexander M M
Reaching first base in the treatment of metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(29):4673-4.
-
2006: van Horssen Remco; Eggermont Alexander M M; ten Hagen Timo L M
Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.
Cytokine & growth factor reviews 2006;17(5):339-48.
-
2006: Hoving Saske; Seynhaeve Ann L B; van Tiel Sandra T; aan de Wiel-Ambagtsheer Gisela; de Bruijn Ernst A; Eggermont Alexander M M; ten Hagen Timo L M
Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
Anti-cancer drugs 2006;17(8):949-59.
-
2006: de Vries E; Steliarova-Foucher E; Spatz A; Ardanaz E; Eggermont A M M; Coebergh J W W
Skin cancer incidence and survival in European children and adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project.
European journal of cancer (Oxford, England : 1990) 2006;42(13):2170-82.
-
2006: Ferenschild Floris T J; Vermaas Maarten; Nuyttens Joost J M E; Graveland Wilfried J; Marinelli Andreas W K S; van der Sijp Joost R; Wiggers Theo; Verhoef Cornelis; Eggermont Alexander M M; de Wilt Johannes H W
Value of intraoperative radiotherapy in locally advanced rectal cancer.
Diseases of the colon and rectum 2006;49(9):1257-65.
-
2006: van Horssen Remco; Rens Joost A P; Brunstein Flavia; Guns Veronique; van Gils Marjon; Hagen Timo L M Ten; Eggermont Alexander M M
Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.
International journal of cancer. Journal international du cancer 2006;119(6):1481-90.
-
2006: van Akkooi Alexander C J; Golab-Schwarz Hannah D; Eggermont Alexander M M; van Geel Albertus N
Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's witness.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2006;30(2):408-10.
-
2006: Tilanus-Linthorst M M A; Alves C; Seynaeve C; Menke-Pluymers M B E; Eggermont A M M; Brekelmans C T M
Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
The British journal of surgery 2006;93(8):961-8.
-
2006: Vermaas M; Verhoef C; Eggermont A M M; de Wilt J H W; Kuiper J W
Utility of repeat radiofrequency ablation to provide long-term local control in recurrent rectal cancer.
Surgery 2006;140(1):120.
-
2006: Wong Sandra L; Morton Donald L; Thompson John F; Gershenwald Jeffrey E; Leong Stanley P L; Reintgen Douglas S; Gutman Haim; Sabel Michael S; Carlson Grant W; McMasters Kelly M; Tyler Douglas S; Goydos James S; Eggermont Alexander M M; Nieweg Omgo E; Cosimi A Benedict; Riker Adam I; G Coit Daniel
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
Annals of surgical oncology 2006;13(6):809-16.
-
2006: de Kanter A Y; Menke-Pluijmers M B E; Henzen-Logmans S C; van Geel A N; van Eijck C J H; Wiggers T; Eggermont A M M
Reasons for failure to identify positive sentinel nodes in breast cancer patients with significant nodal involvement.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(5):498-501.
-
2006: ten Hagen Timo L M; Eggermont Alexander M M
Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(3):241-6.
-
2006: Grünhagen D J; de Wilt J H W; van Geel A N; Eggermont A M M
Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(4):371-80.
-
2006: Eggermont Alexander M M
Randomized trials in melanoma: an update.
Surgical oncology clinics of North America 2006;15(2):439-51.
-
2006: van Horssen Remco; Ten Hagen Timo L M; Eggermont Alexander M M
TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.
The oncologist 2006;11(4):397-408.
-
2006: Winnepenninckx Véronique; Lazar Vladimir; Michiels Stefan; Dessen Philippe; Stas Marguerite; Alonso Soledad R; Avril Marie-Françoise; Ortiz Romero Pablo L; Robert Thomas; Balacescu Ovidiu; Eggermont Alexander M M; Lenoir Gilbert; Sarasin Alain; Tursz Thomas; van den Oord Joost J; Spatz Alain;
Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Journal of the National Cancer Institute 2006;98(7):472-82.
-
2006: Grunhagen Dirk J; de Wilt Johannes H W; Graveland Wilfried J; Verhoef Cornelis; van Geel Albertus N; Eggermont Alexander M M
Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Cancer 2006;106(8):1776-84.
-
2006: de Kanter A Y; Menke-Pluymers M M; Wouters M W J M; Burgmans I; van Geel A N; Eggermont A M M
5-Year follow-up of sentinel node negative breast cancer patients.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(3):282-6.
-
2006: Noorda E M; Vrouenraets B C; Nieweg O E; van Geel A N; Eggermont A M M; Kroon B B R
Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(3):318-24.
-
2006: Grünhagen Dirk J; de Wilt Johannes H W; ten Hagen Timo L M; Eggermont Alexander M M
Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities.
Nature clinical practice. Oncology 2006;3(2):94-103.
-
2006: van Akkooi A C J; de Wilt J H W; Verhoef C; Graveland W J; van Geel A N; Kliffen M; Eggermont A M M
High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
European journal of cancer (Oxford, England : 1990) 2006;42(3):372-80.
-
2006: Grunhagen Dirk J; de Wilt Johannes H W; Graveland Wilfried J; van Geel Albertus N; Eggermont Alexander M M
The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
Cancer 2006;106(1):156-62.
-
2006: Terkivatan Türkan; Kliffen Mike; de Wilt Johannes H W; van Geel Albertus N; Eggermont Alexander M M; Verhoef Cornelis
Giant solitary fibrous tumour of the liver.
World journal of surgical oncology 2006;4():81.
-
2006: Seynhaeve A L B; Vermeulen C E; Eggermont A M M; ten Hagen T L M
Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells.
Cell biochemistry and biophysics 2006;44(1):157-69.
-
2005: Menke-Pluymers M B E; Seynaeve C; van Geel A N; Klijn J G M; Meijers-Heijboer E J; Eggermont A M M
[Preventive surgical prcedures for inherited risk of breast cancer]
Nederlands tijdschrift voor geneeskunde 2005;149(48):2663-7.
-
2005: van Akkooi A C J; de Wilt J H W; van Geel A N; Verhoef C; Eggermont A M M
[Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients]
Nederlands tijdschrift voor geneeskunde 2005;149(45):2538; author reply 2538-9.
-
2005: Ferenschild Floris T J; Vermaas Maarten; Hofer Stefan O; Verhoef Cornelis; Eggermont Alexander M M; de Wilt Johannes H W
Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
World journal of surgery 2005;29(11):1452-7.
-
2005: Grünhagen D J; de Wilt J H W; van Geel A N; Graveland W J; Verhoef C; Eggermont A M M
TNF dose reduction in isolated limb perfusion.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(9):1011-9.
-
2005: Vermaas M; Ferenschild F T J; Hofer S O P; Verhoef C; Eggermont A M M; de Wilt J H W
Primary and secondary reconstruction after surgery of the irradiated pelvis using a gracilis muscle flap transposition.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(9):1000-5.
-
2005: Kruit Wim H J; van Ojik Heidi H; Brichard Vincent G; Escudier Bernard; Dorval Thierry; Dréno Brigitte; Patel Poulam; van Baren Nicolas; Avril Marie-Françoise; Piperno Sophie; Khammari Amir; Stas Marguerite; Ritter Gerd; Lethé Bernard; Godelaine Danièle; Brasseur Francis; Zhang Yi; van der Bruggen Pierre; Boon Thierry; Eggermont Alexander M M; Marchand Marie
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
International journal of cancer. Journal international du cancer 2005;117(4):596-604.
-
2005: van Vliet Marion; van Dijke Cornelis F; Wielopolski Piotr A; ten Hagen Timo L M; Veenland Jifke F; Preda Anda; Loeve Antonius J; Eggermont Alexander M M; Krestin Gabriel P
MR angiography of tumor-related vasculature: from the clinic to the micro-environment.
Radiographics : a review publication of the Radiological Society of North America, Inc 2005;25 Suppl 1():S85-97; discussion S97-8.
-
2005: Eggermont Alexander M M; Suciu Stefan; MacKie Rona; Ruka Wlodzimierz; Testori Alessandro; Kruit Wim; Punt Cornelis J A; Delauney Michelle; Sales François; Groenewegen Gerard; Ruiter Dirk J; Jagiello Izabella; Stoitchkov Konstantin; Keilholz Ulrich; Lienard Danielle;
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Lancet 2005;366(9492):1189-96.
-
2005: Queirolo Paola; Acquati Mirko; Kirkwood John M; Eggermont Alexander M M; Rocca Andrea; Testori Alessandro
Update: current management issues in malignant melanoma.
Melanoma research 2005;15(5):319-24.
-
2005: Grünhagen D J; de Wilt J H W; Verhoef C; van Geel A N; Eggermont A M M
TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(8):912-6.
-
2005: van Ijken M G A; van Etten B; Guetens G; de Bruijn E A; Ten Hagen T L M; Wiggers Th; Eggermont A M M
Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(8):897-904.
-
2005: van Ijken M G A; van Etten B; Brunstein F; ten Hagen T L M; Guetens G; de Wilt J H W; de Bruijn E A; Eggermont A M M
Bio-chemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(8):807-16.
-
2005: Keilholz Ulrich; Punt Cornelis J A; Gore Martin; Kruit Wim; Patel Poulam; Lienard Danielle; Thomas Jose; Proebstle Thomas M; Schmittel Alexander; Schadendorf Dirk; Velu Thierry; Negrier Sylvie; Kleeberg Ulrich; Lehman Frederic; Suciu Stefan; Eggermont Alexander M M
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6747-55.
-
2005: de Vries E; Boniol M; Severi G; Eggermont A M M; Autier P; Bataille V; Doré J F; Coebergh J W W
Public awareness about risk factors could pose problems for case-control studies: the example of sunbed use and cutaneous melanoma.
European journal of cancer (Oxford, England : 1990) 2005;41(14):2150-4.
-
2005: Takkenberg R B; Vrouenraets B C; van Geel A N; Nieweg O E; Noorda E M; Eggermont A M M; Kroon B B R
Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Journal of surgical oncology 2005;91(2):107-11.
-
2005: Grünhagen Dirk J; van Etten Boudewijn; Brunstein Flavia; Graveland Wilfried J; van Geel Albertus N; de Wilt Johannes H W; Eggermont Alexander M M
Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Annals of surgical oncology 2005;12(8):609-15.
-
2005: Brunstein Flavia; Santos Ivan Dunshee de Abranches Oliveira; Ferreira Lydia Masako; van Tiel Sandra T; Eggermont Alexander M M; Ten Hagen Timo L M
Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.
Acta cirúrgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia 2005;20(4):275-9.
-
2005: Pawlik Timothy M; Ross Merrick I; Thompson John F; Eggermont Alexander M M; Gershenwald Jeffrey E
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4588-90.
-
2005: Tilanus-Linthorst Madeleine M A; Kriege Mieke; Boetes Carla; Hop Wim C J; Obdeijn Inge-Marie; Oosterwijk Jan C; Peterse Hans L; Zonderland Harmine M; Meijer Sybren; Eggermont Alexander M M; de Koning Harry J; Klijn Jan G M; Brekelmans Cecile T M
Hereditary breast cancer growth rates and its impact on screening policy.
European journal of cancer (Oxford, England : 1990) 2005;41(11):1610-7.
-
2005: Eggermont A M M
Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):995-6.
-
2005: Hoving Saske; Seynhaeve Ann L B; van Tiel Sandra T; Eggermont Alexander M M; ten Hagen Timo L M
Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.
Anti-cancer drugs 2005;16(6):667-74.
-
2005: Grünhagen Dirk J; Eggermont Alexander M M; van Geel Albertus N; Graveland Wilfried J; deWilt Johannes H W
Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases.
Melanoma research 2005;15(3):179-84.
-
2005: Grünhagen Dirk J; Brunstein Flavia; Graveland Wilfried J; van Geel Albertus N; de Wilt Johannes H W; Eggermont Alexander M M
Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg.
Annals of surgical oncology 2005;12(6):473-9.
-
2005: Lans T E; Grünhagen D J; de Wilt J H W; van Geel A N; Eggermont A M M
Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
Annals of surgical oncology 2005;12(5):406-11.
-
2005: Hoving Saske; Brunstein Flavia; aan de Wiel-Ambagtsheer Gisela; van Tiel Sandra T; de Boeck Gert; de Bruijn Ernst A; Eggermont Alexander M M; ten Hagen Timo L M
Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Cancer research 2005;65(10):4300-8.
-
2005: Vermaas Maarten; Ferenschild Floris T J; Nuyttens Joost J M E; Marinelli Andreas W K S; Wiggers Theo; van der Sijp Joost R M M; Verhoef Cornelis; Graveland Wilfried J; Eggermont Alexander M M; de Wilt Johannes H W
Preoperative radiotherapy improves outcome in recurrent rectal cancer.
Diseases of the colon and rectum 2005;48(5):918-28.
-
2005: van Etten Boudewijn; Eggermont Alexander M M; van Tiel Sandra T; Ambagtsheer G; de Wilt Johannes H W; ten Hagen Timo L M
Gene therapy in in vivo isolated perfusion models.
Current gene therapy 2005;5(2):195-202.
-
2005: Hoving Saske; van Tiel Sandra T; Eggermont Alexander M M; ten Hagen Timo L M
Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.
Anticancer research 2005;25(2A):743-50.
-
2005: Zhang Yi; Sun Zhaojun; Nicolay Hugues; Meyer Ralf G; Renkvist Nicolina; Stroobant Vincent; Corthals Jurgen; Carrasco Javier; Eggermont Alexander M M; Marchand Marie; Thielemans Kris; Wölfel Thomas; Boon Thierry; van der Bruggen Pierre
Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(4):2404-11.
-
2005: Kapma M R; Vrouenraets B C; Nieweg O E; van Geel A N; Noorda E M; Eggermont A M M; Kroon B B R
Major amputation for intractable extremity melanoma after failure of isolated limb perfusion.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(1):95-9.
-
2005: Eggermont Alexander M M
Reducing the need for sentinel node procedures by ultrasound examination of regional lymph nodes.
Annals of surgical oncology 2005;12(1):3-5.
-
2005: Bannink Marjolein; Kruit Wim H J; Van Gool Arthur R; Mulder Paul G H; Sleijfer Stefan; Eggermont Alexander M M; Stoter Gerrit; Fekkes Durk
Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients.
Progress in neuro-psychopharmacology & biological psychiatry 2005;29(1):109-14.
-
2005: Eggermont Alexander M M
Current status of interferon-alpha in the treatment of melanoma.
Cancer chemotherapy and biological response modifiers 2005;22():729-37.
-
2004: Grünhagen Dirk J; Brunstein Flavia; Graveland Wilfried J; van Geel Albertus N; de Wilt Johannes H W; Eggermont Alexander M M
One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
Annals of surgery 2004;240(6):939-47; discussion 947-8.
-
2004: Preda A; Wielopolski P A; Ten Hagen T L M; van Vliet M; Veenland J F; Ambagtsheer G; van Tiel S T; Vogel M W; Eggermont A M M; Krestin G P; van Dijke C F
Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.
Magma (New York, N.Y.) 2004;17(3-6):296-302.
-
2004: Noorda Eva M; Vrouenraets Bart C; Nieweg Omgo E; van Geel Bert N; Eggermont Alexander M M; Kroon Bin B R
Isolated limb perfusion for unresectable melanoma of the extremities.
Archives of surgery (Chicago, Ill. : 1960) 2004;139(11):1237-42.
-
2004: Brunstein Flavia; Hoving Saske; Seynhaeve Ann L B; van Tiel Sandra T; Guetens Gunther; de Bruijn Ernst A; Eggermont Alexander M M; ten Hagen Timo L M
Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
Journal of the National Cancer Institute 2004;96(21):1603-10.
-
2004: van Etten B; Eggermont A M M; Ambagtsheer G; van Tiel S T; ten Hagen T L M
Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.
British journal of cancer 2004;91(8):1610-3.
-
2004: de Vries E; Bray F I; Eggermont A M M; Coebergh J W W;
Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2004;13(5):387-95.
-
2004: Eggermont Alexander M M; Kirkwood John M
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
European journal of cancer (Oxford, England : 1990) 2004;40(12):1825-36.
-
2004: van IJken M G A; de Bruijn E A; ten Hagen T L M; de Boeck G; van Eijck C H J; Eggermont A M M
Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: a pharmacokinetic study in pigs.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2004;30(6):699-707.
-
2004: van IJken M G A; van Etten B; Guetens G; ten Hagen T L M; Jeekel J; de Bruijn E A; Eggermont A M M; van Eijck C H J
Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase I-II trial.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2004;30(6):671-80.
-
2004: Van Etten Boudewijn; Van Tiel Sandra T; Ambagtsheer Gisela; Eggermont Alexander M M; Ten Hagen Timo L M
Isolated limb perfusion based anti-p21ras gene therapy in a rat rhabdomyosarcoma.
Anticancer research 2004;24(4):2295-301.
-
2004: Lans T E; Van Horssen R; Eggermont A M M; Ten Hagen T L M
Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
Anticancer research 2004;24(4):2243-8.
-
2004: Van Gool A R; Van Ojik H H; Kruit W H J; Mulder P G H; Fekkes D; Bannink M; Scharpé S; Stoter G; Eggermont A M M; Maes M; Verkerk R
Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(7):411-5.
-
2004: Van Gool Arthur R; van Ojik Heidi H; Kruit Wim H J; Bannink Marjolein; Mulder Paul G H; Eggermont Alexander M M; Stoter Gerrit; Fekkes Durk
Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.
Anti-cancer drugs 2004;15(6):587-91.
-
2004: van Etten Boudewijn; Brunstein Flavia; van IJken Marc G A; Marinelli Andreas W K S; Verhoef Cornelis; van der Sijp Joost R M; Guetens Gunther; de Boeck Gert; de Bruijn Ernst A; de Wilt Johannes H W; Eggermont Alexander M M
Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
Annals of surgical oncology 2004;11(6):598-605.
-
2004: ten Hagen T L M; Hoving S; Ambagtsheer G; van Tiel S T; Eggermont A M M
Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.
British journal of cancer 2004;90(9):1830-2.
-
2004: Noorda Eva M; Takkenberg Bart; Vrouenraets Bart C; Nieweg Omgo E; van Geel Bert N; Eggermont Alexander M M; Hart Guus A M; Kroon Bin B R
Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
Annals of surgical oncology 2004;11(5):491-9.
-
2004: de Wilt Johannes H W; van Etten Boudewijn; Verhoef Cornelis; Eggermont Alexander M M
Isolated hepatic perfusion: experimental evidence and clinical utility.
The Surgical clinics of North America 2004;84(2):627-41.
-
2004: Brouckaert Peter; Takahashi Nozomi; van Tiel Sandra T; Hostens Jeroen; Eggermont Alexander M M; Seynhaeve Ann L B; Fiers Walter; ten Hagen Timo L M
Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.
International journal of cancer. Journal international du cancer 2004;109(3):442-8.
-
2004: Kleeberg U R; Suciu S; Bröcker E B; Ruiter D J; Chartier C; Liénard D; Marsden J; Schadendorf D; Eggermont A M M;
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
European journal of cancer (Oxford, England : 1990) 2004;40(3):390-402.
-
2004: Eggermont A M M; Brunstein F; Grünhagen D; ten Hagen T L M
Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv107-12.
-
2004: Grünhagen Dirk J; Brunstein Flavia; ten Hagen Timo L M; van Geel Albertus N; de Wilt Johannes H W; Eggermont Alexander M M
TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas.
Cancer treatment and research 2004;120():65-79.
-
2004: Hagen Timo L M ten; Eggermont Alexander M M
Tumor vascular therapy with TNF: critical review on animal models.
Methods in molecular medicine 2004;98():227-46.
-
2003: Noorda E M; Vrouenraets B C; Nieweg O E; van Geel A N; Eggermont A M M; Kroon B B R
Prognostic factors for survival after isolated limb perfusion for malignant melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2003;29(10):916-21.
-
2003: Autier Philippe; Coebergh Jan Willem; Boniol Mathieu; Dore Jean-François; de Vries Esther; Eggermont Alexander M M
Management of melanoma patients: benefit of intense follow-up schedule is not demonstrated.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(19):3707; author reply 3707-8.
-
2003: Hofland Jan; Tenbrinck Robert; Eggermont Alexander M M; Eijck Casper H J; Gommers Diederik; Erdmann Wilhelm
Effects of simultaneous aortocaval occlusion on oxygen consumption in patients.
Clinical physiology and functional imaging 2003;23(5):275-81.
-
2003: Van Gool Arthur R; Fekkes Durk; Kruit Wim H J; Mulder Paul G H; Ten Hagen Timo L M; Bannink Marjolein; Maes Michael; Eggermont Alexander M M
Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients.
Psychiatry research 2003;119(1-2):125-32.
-
2003: Eggermont Alexander M M; de Wilt Johannes H W; ten Hagen Timo L M
Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
The lancet oncology 2003;4(7):429-37.
-
2003: Cook Martin G; Green Margaret A; Anderson Brian; Eggermont Alexander M M; Ruiter Dirk J; Spatz Alain; Kissin Mark W; Powell Barry W E M;
The development of optimal pathological assessment of sentinel lymph nodes for melanoma.
The Journal of pathology 2003;200(3):314-9.
-
2003: de Vries E; Schouten L J; Visser O; Eggermont A M M; Coebergh J W W;
Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient?
European journal of cancer (Oxford, England : 1990) 2003;39(10):1439-46.
-
2003: Zhang Yi; Chaux Pascal; Stroobant Vincent; Eggermont Alexander M M; Corthals Jurgen; Maillère Bernard; Thielemans Kris; Marchand Marie; Boon Thierry; Van Der Bruggen Pierre
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(1):219-25.
-
2003: ten Hagen Timo L M; Eggermont A M M
Solid tumor therapy: manipulation of the vasculature with TNF.
Technology in cancer research & treatment 2003;2(3):195-203.
-
2003: Van Geel Albert N; Contant Caroline M E; Wai Rudi Tjong Joe; Schmitz Paul I M; Eggermont Alexander M M; Menke-Pluijmers Marian M E
Mastectomy by inverted drip incision and immediate reconstruction: data from 510 cases.
Annals of surgical oncology 2003;10(4):389-95.
-
2003: de Kanter A Y; Arends P P A M; Eggermont A M M; Wiggers T
Radiation protection for the sentinel node procedure in breast cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2003;29(4):396-9.
-
2003: Eggermont Alexander M M; van Geel Albertus N; de Wilt Johannes H W; ten Hagen Timo L M
The role of isolated limb perfusion for melanoma confined to the extremities.
The Surgical clinics of North America 2003;83(2):371-84, ix.
-
2003: Mellink W A M; Dulmen A M V; Wiggers Th; Spreeuwenberg P M M; Eggermont A M M; Bensing J M
Cancer patients seeking a second surgical opinion: results of a study on motives, needs, and expectations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1492-7.
-
2003: Hofland J; Tenbrinck R; van Eijck C H J; Eggermont A M M; Gommers D; Erdmann W
Comparison of closed circuit and Fick-derived oxygen consumption in patients undergoing simultaneous aortocaval occlusion.
Anaesthesia 2003;58(4):377-84.
-
2003: de Vries Mark R; ten Hagen Timo L M; Marinelli Andreas W K S; Eggermont Alexander M M
Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies.
Anticancer research 2003;23(2C):1811-23.
-
2003: Eggermont Alexander M M; ten Hagen Timo L M
Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.
Current oncology reports 2003;5(2):79-80.
-
2003: Van Gool Arthur R; Kruit Wim H J; Engels Frederike K; Stoter Gerrit; Bannink Marjolein; Eggermont Alexander M M
Neuropsychiatric side effects of interferon-alfa therapy.
Pharmacy world & science : PWS 2003;25(1):11-20.
-
2003: van Etten B; de Vries M R; van IJken M G A; Lans T E; Guetens G; Ambagtsheer G; van Tiel S T; de Boeck G; de Bruijn E A; Eggermont A M M; ten Hagen T L M
Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
British journal of cancer 2003;88(2):314-9.
-
2003: van Etten Boudewijn; van Geel Albertus N; de Wilt Johannes H W; Eggermont Alexander M M
Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors.
Annals of surgical oncology 2003;10(1):32-7.
-
2003: Marchand M; Punt C J A; Aamdal S; Escudier B; Kruit W H J; Keilholz U; Håkansson L; van Baren N; Humblet Y; Mulders P; Avril M-F; Eggermont A M M; Scheibenbogen C; Uiters J; Wanders J; Delire M; Boon T; Stoter G
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
European journal of cancer (Oxford, England : 1990) 2003;39(1):70-7.
-
2003: Van Geel Albert N; Eggermont Alexander M M; Hanssens Patrick E J; Schmitz Paul I M
Factors Influencing Prognosis After Initial Inadequate Excision (IIE) for Soft Tissue Sarcoma.
Sarcoma 2003;7(3-4):159-65.
-
2003: Hofland Jan; Tenbrinck Robert; Eggermont Alexander M M; Erdmann Wilhelm
Comparison of the influence of xenon vs. isoflurane on ventilation-perfusion relationships in patients undergoing simultaneous aortocaval occlusion.
Advances in experimental medicine and biology 2003;540():61-9.
-
2003: Eggermont Alexander M M; Punt Cornelis J A
Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
American journal of clinical dermatology 2003;4(8):531-6.
-
2002: Lans T E; de Wilt J H W; van Geel A N; Eggermont A M M
Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma.
Annals of surgical oncology 2002;9(10):1004-9.
-
2002: Noorda E M; Vrouenraets B C; Nieweg O E; van Geel A N; Eggermont A M M; Kroon B B R
Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
Annals of surgical oncology 2002;9(10):968-74.
-
2002: Tilanus-Linthorst Madeleine; Verhoog Leon; Obdeijn Inge-Marie; Bartels Karina; Menke-Pluymers Marian; Eggermont Alexander; Klijn Jan; Meijers-Heijboer Hanne; van der Kwast Theo; Brekelmans Cecile
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
International journal of cancer. Journal international du cancer 2002;102(1):91-5.
-
2002: Eggermont Alexander M M
Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.
Expert review of anticancer therapy 2002;2(5):563-9.
-
2002: Lans T E; ten Hagen T L M; van Horssen R; Wu P C; van Tiel S T; Libutti S K; Alexander H R; Eggermont A M M
Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
Annals of surgical oncology 2002;9(8):812-9.
-
2002: Nieweg O E; Eggermont A M M; Kroon B B R
[Sentinel node biopsy in melanoma: some critical questions]
Nederlands tijdschrift voor geneeskunde 2002;146(38):1774-7.
-
2002: Contant C M E; Menke-Pluijmers M B E; Seynaeve C; Meijers-Heijboer E J; Klijn J G M; Verhoog L C; Tjong Joe Wai R; Eggermont A M M; van Geel A N
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2002;28(6):627-32.
-
2002: De Vries E; Doré J F; Autier P; Eggermont A M M; Coebergh J W W;
Patients' perception of the cause of their melanoma differs from that of epidemiologists.
The British journal of dermatology 2002;147(2):388-9.
-
2002: Eggermont Alexander M M; Gore Martin
European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma.
Seminars in oncology 2002;29(4):382-8.
-
2002: Keilholz U; Martus P; Punt C J A; Kruit W; Mooser G; Schadendorf D; Liénard D; Dummer R; Koller J; Voit C; Eggermont A M M
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
European journal of cancer (Oxford, England : 1990) 2002;38(11):1501-11.
-
2002: Contant C M E; Swaak A J G; Obdeijn A I M; van der Holt B; Tjong Joe Wai R; van Geel A N; Eggermont A M M
A prospective study on silicone breast implants and the silicone-related symptom complex.
Clinical rheumatology 2002;21(3):215-9.
-
2002: Seynhaeve A L B; de Wilt J H W; van Tiel S T; Eggermont A M M; ten Hagen T L M
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.
British journal of cancer 2002;86(7):1174-9.
-
2002: Stam T C; Swaak A J G; Kruit W H J; Eggermont A M M
Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b.
European journal of clinical investigation 2002;32 Suppl 1():79-83.
-
2002: Eggermont Alexander M M
European approach to the treatment of malignant melanoma.
Current opinion in oncology 2002;14(2):205-11.
-
2002: Eggermont A M M; Keilholz U; Autier Ph; Ruiter D J; Lehmann F; Lienard D;
The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 4():S114-9.
-
2002: ten Hagen Timo L M; Eggermont Alexander M M
Manipulation of the tumour-associated vasculature to improve tumour therapy.
Journal of liposome research 2002;12(1-2):149-54.
-
2002: Hofland J; Tenbrinck R; van IJken M G A; van Eijck C H J; Eggermont A M M; Erdmann W
Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy.
British journal of anaesthesia 2002;88(2):193-8.
-
2002: van Etten B; ten Hagen T L M; de Vries M R; Ambagtsheer G; Huet T; Eggermont A M M
Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras.
British journal of cancer 2002;86(3):436-42.
-
2002: ten Hagen Timo L M; Seynhaeve Ann L B; van Tiel Sandra T; Ruiter Dirk J; Eggermont Alexander M M
Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.
International journal of cancer. Journal international du cancer 2002;97(1):115-20.
-
2002: van der Veen Alexander H; ten Hagen Timo L M; Seynhaeve Ann L B; Eggermont Alexander M M
Lack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin.
Cancer investigation 2002;20(4):499-508.
-
2001: Punt C J; Eggermont A M
Adjuvant interferon-alpha for melanoma revisited: news from old and new studies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(12):1663-6.
-
2001: Ghanem G; Loir B; Morandini R; Sales F; Lienard D; Eggermont A; Lejeune F;
On the release and half-life of S100B protein in the peripheral blood of melanoma patients.
International journal of cancer. Journal international du cancer 2001;94(4):586-90.
-
2001: Eggermont A; Newell H
Translational research in clinical trials: the only way forward.
European journal of cancer (Oxford, England : 1990) 2001;37(16):1965.
-
2001: Eggermont A M
The role interferon-alpha in malignant melanoma remains to be defined.
European journal of cancer (Oxford, England : 1990) 2001;37(17):2147-53.
-
2001: Lejeune F J; Kroon B B; Di Filippo F; Hoekstra H J; Santinami M; Liénard D; Eggermont A M
Isolated limb perfusion: the European experience.
Surgical oncology clinics of North America 2001;10(4):821-32, ix.
-
2001: Eggermont A M; Keilholz U; Testori A; Cook M; Lienard D; Ruiter D J
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
Annals of surgical oncology 2001;8(9 Suppl):38S-40S.
-
2001: Eggermont A M; ten Hagen T L
Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
Current oncology reports 2001;3(4):359-67.
-
2001: Vrouenraets B C; Eggermont A M; Hart A A; Klaase J M; van Geel A N; Nieweg O E; Kroon B B
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2001;27(4):390-5.
-
2001: de Wilt J H; Bout A; Eggermont A M; van Tiel S T; de Vries M W; ten Hagen T L; de Roos W K; Valerio D; van der Kaaden M E
Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats.
Human gene therapy 2001;12(5):489-502.
-
2001: Koelemij R; Hagenaars M; Ensink N G; Eggermont A M; Van De Velde C J; Fleuren G J; Kuppen P J
Administration of BiMAb-retargeted T cells in a rat hepatic metastases colon tumour model results in T-cell tumour infiltration independent of the route of administration.
Scandinavian journal of immunology 2001;53(3):277-81.
-
2000: de Roos W K; de Wilt J H; van Der Kaaden M E; Manusama E R; de Vries M W; Bout A; ten Hagen T L; Valerio D; Eggermont A M
Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.
Annals of surgery 2000;232(6):814-21.
-
2000: Jonges L E; Giezeman-Smits K M; van Vlierberghe R L; Ensink N G; Hagenaars M; Joly E; Eggermont A M; van de Velde C J; Fleuren G J; Kuppen P J
NK cells modulate MHC class I expression on tumor cells and their susceptibility to lysis.
Immunobiology 2000;202(4):326-38.
-
2000: de Kanter A Y; van Geel A N; Paul M A; van Eijck C H; Henzen-Logmans S C; Kruyt R H; Krenning E P; Eggermont A M; Wiggers T
Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2000;26(7):652-6.
-
2000: Ferrier C M; Suciu S; van Geloof W L; Straatman H; Eggermont A M; Koops H S; Kroon B B; Lejeune F J; Kleeberg U R; van Muijen G N; Ruiter D J
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
British journal of cancer 2000;83(10):1351-9.
-
2000: de Wilt J H; Manusama E R; van Etten B; van Tiel S T; Jorna A S; Seynhaeve A L; ten Hagen T L; Eggermont A M
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
British journal of cancer 2000;83(9):1176-82.
-
2000: de Wilt J H; Soma G; ten Hagen T L; Kanou J; Takagi K; Nooijen P T; Seynhaevel A L; Eggermont A M
Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
Anticancer research 2000;20(5B):3491-6.
-
2000: van Der Veen A H; ten Hagen T L; de Wilt J H; van Ijken M G; Eggermont A M
An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application.
Anticancer research 2000;20(5B):3467-74.
-
2000: Ten Hagen T L; Van Der Veen A H; Nooijen P T; Van Tiel S T; Seynhaeve A L; Eggermont A M
Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
International journal of cancer. Journal international du cancer 2000;87(6):829-37.
-
2000: Eggermont A M
TNF registered in Europe: does TNF get a second chance?
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):505-6.
-
2000: van Ijken M G; van Etten B; de Wilt J H; van Tiel S T; ten Hagen T L; Eggermont A M
Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):449-55.
-
2000: Eggermont A M; van IJken M G; van Etten B; van der Sijp J R; ten Hagen T L; Wiggers T; Oudkerk M; de Boeck G; de Bruijn E A
Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure.
Hepato-gastroenterology 2000;47(33):776-81.
-
2000: Stam T C; Swaak A J; de Vries M R; ten Hagen T L; Eggermont A M
Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage.
Annals of surgical oncology 2000;7(4):268-75.
-
2000: Stam T C; Swaak A J; Kruit W H; Stoter G; Eggermont A M
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
European journal of clinical investigation 2000;30(4):336-43.
-
2000: de Wilt J H; ten Hagen T L; de Boeck G; van Tiel S T; de Bruijn E A; Eggermont A M
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
British journal of cancer 2000;82(5):1000-3.
-
2000: van der Veen A H; de Wilt J H; Eggermont A M; van Tiel S T; Seynhaeve A L; ten Hagen T L
TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
British journal of cancer 2000;82(4):973-80.
-
2000: Keilholz U; Eggermont A M
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
The cancer journal from Scientific American 2000;6 Suppl 1():S99-103.
-
2000: Hagenaars M; Ensink N G; Eggermont A M; van der Velde E A; van de Velde C J; Fleuren G J; Kuppen P J
Endogenous natural killer cells do not play a role in antitumor effects induced by interleukin-2 in a syngeneic rat colon tumor model.
Cancer immunology, immunotherapy : CII 2000;48(10):561-8.
-
2000: Hagenaars M; Koelemij R; Ensink N G; van Eendenburg J D; van Vlierberghe R L; Eggermont A M; van de Velde C J; Fleuren G J; Kuppen P J
The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma.
Clinical & experimental metastasis 2000;18(4):281-9.
-
2000: Hagenaars M; Ensink N G; Basse P H; Hokland M; Nannmark U; Eggermont A M; van de Velde C J; Fleuren G J; Kuppen P J
The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy?
Clinical & experimental metastasis 2000;18(2):189-96.
-
2000: Eggermont A M
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2000;157():178-89.
-
1999: de Kanter A Y; van Eijck C H; van Geel A N; Kruijt R H; Henzen S C; Paul M A; Eggermont A M; Wiggers T
Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer.
The British journal of surgery 1999;86(11):1459-62.
-
1999: Koelemij R; Kuppen P J; van de Velde C J; Fleuren G J; Hagenaars M; Eggermont A M
Bispecific antibodies in cancer therapy, from the laboratory to the clinic.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(6):514-24.
-
1999: Liénard D; Eggermont A M; Koops H S; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune F J
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Melanoma research 1999;9(5):491-502.
-
1999: Giezeman-Smits K M; Gorter A; van Vlierberghe R L; v Eendenburg J D; Eggermont A M; Fleuren G J; Kuppen P J
The regulatory role of CD45 on rat NK cells in target cell lysis.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):71-6.
-
1999: Vrouenraets B C; Kroon B B; Ogilvie A C; van Geel A N; Nieweg O E; Swaak A J; Eggermont A M
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Annals of surgical oncology 1999;6(4):405-12.
-
1999: De Vries M R; Borel Rinkes I H; Swaak A J; Hack C E; Van De Velde C J; Wiggers T; Tollenaar R A; Kuppen P J; Eggermont A M
Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
European journal of clinical investigation 1999;29(6):553-60.
-
1999: Vrouenraets B C; Hart G A; Eggermont A M; Klaase J M; van Geel B N; Nieweg O E; Kroon B B
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.
Journal of the American College of Surgeons 1999;188(5):522-30.
-
1999: de Wilt J H; Manusama E R; van Tiel S T; van Ijken M G; ten Hagen T L; Eggermont A M
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.
British journal of cancer 1999;80(1-2):161-6.
-
1999: Stam T C; Eggermont A M; Swaak A J
Effects of tumour necrosis factor alpha and melphalan on the cytokine production of circulating T cells in patients with cancer.
European journal of clinical investigation 1999;29(3):256-63.
-
1999: Feelders R A; Swaak A J; Romijn J A; Eggermont A M; Tielens E T; Vreugdenhil G; Endert E; van Eijk H G; Berghout A
Characteristics of recovery from the euthyroid sick syndrome induced by tumor necrosis factor alpha in cancer patients.
Metabolism: clinical and experimental 1999;48(3):324-9.
-
1999: Olieman A F; Liénard D; Eggermont A M; Kroon B B; Lejeune F J; Hoekstra H J; Koops H S
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
Archives of surgery (Chicago, Ill. : 1960) 1999;134(3):303-7.
-
1999: Chaux P; Vantomme V; Stroobant V; Thielemans K; Corthals J; Luiten R; Eggermont A M; Boon T; van der Bruggen P
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.
The Journal of experimental medicine 1999;189(5):767-78.
-
1999: Hagenaars M; Ensink N G; Jonges L E; Chambers W H; Eggermont A M; van de Velde C J; Fleuren G J; Kuppen P J
The development of a bi-specific anti-CD161A x anti-tumor antibody for rat NK cell targeting.
Immunobiology 1999;200(1):31-48.
-
1999: van der Veen A H; Seynhaeve A L; Breurs J; Nooijen P T; Marquet R L; Eggermont A M
In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
British journal of cancer 1999;79(3-4):433-9.
-
1999: Manusama E R; De Wilt J H; Ten Hagen T L; Marquet R L; Eggermont A M
Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats.
Oncology reports 1999;6(1):173-7.
-
1998: van Ijken M G; de Bruijn E A; de Boeck G; ten Hagen T L; van der Sijp J R; Eggermont A M
Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.
Annals of surgery 1998;228(6):763-70.
-
1998: Hagenaars M; Zwaveling S; Kuppen P J; Ensink N G; Eggermont A M; Hokland M E; Basse P H; van de Velde C J; Fleuren G J; Nannmark U
Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses.
International journal of cancer. Journal international du cancer 1998;78(6):783-9.
-
1998: Eggermont A M
TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives.
Anticancer research 1998;18(5D):3899-905.
-
1998: Koops H S; Vaglini M; Suciu S; Kroon B B; Thompson J F; Göhl J; Eggermont A M; Di Filippo F; Krementz E T; Ruiter D; Lejeune F J
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2906-12.
-
1998: van der Veen A H; Eggermont A M; Seynhaeve A L; van Tiel; ten Hagen T L
Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats.
International journal of cancer. Journal international du cancer 1998;77(6):901-6.
-
1998: Manusama E R; Nooijen P T; Stavast J; de Wilt J H; Marquet R L; Eggermont A M
Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats.
The Journal of surgical research 1998;78(2):169-75.
-
1998: Eggermont A M
Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma.
European journal of cancer (Oxford, England : 1990) 1998;34 Suppl 3():S22-6.
-
1998: Schraffordt Koops H; Eggermont A M; Liènard D; Kroon B B; Hoekstra H J; van Geel A N; Nieweg O E; Lejeune F J
Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1998;48(1):1-4.
-
1998: Feelders R A; Vreugdenhil G; Eggermont A M; Kuiper-Kramer P A; van Eijk H G; Swaak A J
Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients.
European journal of clinical investigation 1998;28(7):520-7.
-
1998: Manusama E R; Nooijen P T; Ten Hagen T L; Van Der Veen A H; De Vries M W; De Wilt J H; Van Ijken M G; Marquet R L; Eggermont A M
Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program.
Seminars in surgical oncology 1998;14(3):232-7.
-
1998: Schraffordt Koops H; Eggermont A M; Liénard D; Kroon B B; Hoekstra H J; Van Geel A N; Nieweg O E; Lejeune F J
Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas.
Seminars in surgical oncology 1998;14(3):210-4.
-
1998: Lejeune F; Liénard D; Eggermont A
Regional Administration of Recombinant Tumour Necrosis Factor-alpha in Cancer, with Special Reference to Melanoma.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 1998;9(3):211-8.
-
1998: van de Vrie W; Marquet R L; Stoter G; De Bruijn E A; Eggermont A M
In vivo model systems in P-glycoprotein-mediated multidrug resistance.
Critical reviews in clinical laboratory sciences 1998;35(1):1-57.
-
1998: Giezeman-Smits K M; Jonges L E; Chambers W H; Brisette-Storkus C S; Van Vlierberghe R L; Van Eendenburg J D; Eggermont A M; Fleuren G J; Kuppen P J
Novel monoclonal antibodies against membrane structures that are preferentially expressed on IL-2-activated rat NK cells.
Journal of leukocyte biology 1998;63(2):209-15.
-
1998: Hagenaars M; Ensink N G; Koelemij R; Basse P H; Eggermont A M; van de Velde C J; Fleuren G J; Kuppen P J
Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration.
International journal of cancer. Journal international du cancer 1998;75(2):233-8.
-
1998: de Vries M R; Borel Rinkes I H; van de Velde C J; Wiggers T; Tollenaar R A; Kuppen P J; Vahrmeijer A L; Eggermont A M
Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;147():107-19.
-
1997: Eggermont A M
Is limb amputation necessary for locally advanced soft tissue sarcomas? Contra.
European journal of cancer (Oxford, England : 1990) 1997;33(14):2298-300.
-
1997: Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman W A; Eggermont A; Lejeune F
Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
Cytokine 1997;9(12):1034-42.
-
1997: Giezeman-Smits K M; Gorter A; Nagelkerke J F; van Vlierberghe R L; van Eendenburg J; Eggermont A M; Fleuren G J; Kuppen P J
Characterization of three new membrane structures on rat NK cells which are involved in activation of the lytic machinery.
Immunobiology 1997;197(5):429-43.
-
1997: Eggermont A M; Schraffordt Koops H; Klausner J M; Liénard D; Kroon B B; Schlag P M; Ben-Ari G; Lejeune F J
Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
Seminars in oncology 1997;24(5):547-55.
-
1997: Eggermont A M
The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.
Melanoma research 1997;7 Suppl 2():S127-31.
-
1997: Kuppen P J; Jonges L E; van de Velde C J; Vahrmeijer A L; Tollenaar R A; Borel Rinkes I H; Eggermont A M
Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
British journal of cancer 1997;75(10):1497-500.
-
1997: Borel Rinkes I H; de Vries M R; Jonker A M; Swaak T J; Hack C E; Nooyen P T; Wiggers T; Eggermont A M
Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
British journal of cancer 1997;75(10):1447-53.
-
1997: Van de Vrie W; Marquet R L; Eggermont A M
Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour.
Journal of cancer research and clinical oncology 1997;123(1):21-4.
-
1996: Nooijen P T; Manusama E R; Eggermont A M; Schalkwijk L; Stavast J; Marquet R L; de Waal R M; Ruiter D J
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
British journal of cancer 1996;74(12):1908-15.
-
1996: Eggermont A M; Schraffordt Koops H; Klausner J M; Kroon B B; Schlag P M; Liénard D; van Geel A N; Hoekstra H J; Meller I; Nieweg O E; Kettelhack C; Ben-Ari G; Pector J C; Lejeune F J
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Annals of surgery 1996;224(6):756-64; discussion 764-5.
-
1996: Sonneveld E J; Vrouenraets B C; van Geel B N; Eggermont A M; Klaase J M; Nieweg O E; van Dongen J A; Kroon B B
Systemic toxicity after isolated limb perfusion with melphalan for melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1996;22(5):521-7.
-
1996: Eggermont A M; Schraffordt Koops H; Liénard D; Kroon B B; van Geel A N; Hoekstra H J; Lejeune F J
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2653-65.
-
1996: Kruit W H; Punt C J; Goey S H; de Mulder P H; Gratama J W; Eggermont A M; Bolhuis R L; Stoter G
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
British journal of cancer 1996;74(6):951-5.
-
1996: Giezeman-Smits K M; Kuppen P J; Ensink N G; Eggermont A M; Stals F; Wonigeit K; Fleuren G J
The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells.
Immunobiology 1996;195(3):286-99.
-
1996: Klop W M; Vrouenraets B C; van Geel B N; Eggermont A M; Klaase J M; Nieweg O E; Kroon B B
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Journal of the American College of Surgeons 1996;182(6):467-72.
-
1996: van Ginkel R J; Hoekstra H J; Eggermont A M; Pras E; Koops H S
Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan.
Archives of surgery (Chicago, Ill. : 1960) 1996;131(6):672-4.
-
1996: Manusama E R; Nooijen P T; Stavast J; Durante N M; Marquet R L; Eggermont A M
Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat.
The British journal of surgery 1996;83(4):551-5.
-
1996: Manusama E R; Stavast J; Durante N M; Marquet R L; Eggermont A M
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1996;22(2):152-7.
-
1996: Goey S H; Eggermont A M; Oskam R; Wiggers T; Bolhuis R L; Stoter G
Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: a phase IA-B study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(3):317-9.
-
1996: Nooijen P T; Eggermont A M; Verbeek M M; Schalkwijk L; Buurman W A; de Waal R M; Ruiter D J
Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(1):33-44.
-
1996: van Ravenswaay Claasen H H; Eggermont A M
Intraperitoneal immunotherapy of cancer: a review of options for treatment.
Cancer treatment and research 1996;82():13-40.
-
1996: Eggermont A M
Treatment of melanoma in-transit metastases confined to the limb.
Cancer surveys 1996;26():335-49.
-
1996: Van de Vrie W; Schellens J H; Loss W J; Kolker H J; Verwey J; Stoter G; Durante N M; Eggermont A M
Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.
Journal of cancer research and clinical oncology 1996;122(7):403-8.
-
1995: Goey S H; Eggermont A M; Punt C J; Slingerland R; Gratama J W; Oosterom R; Oskam R; Bolhuis R L; Stoter G
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
British journal of cancer 1995;72(5):1283-8.
-
1995: Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi M I; Di Re E M; Eggermont A M; Goey S H; Gratama J W; Lamers C H
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
Journal of the National Cancer Institute 1995;87(19):1463-9.
-
1995: Renard N; Nooijen P T; Schalkwijk L; De Waal R M; Eggermont A M; Liénard D; Kroon B B; Lejeune F J; Ruiter D J
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha.
The Journal of pathology 1995;176(3):279-87.
-
1995: Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Schmitz P
[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience]
Bulletin du cancer 1995;82(7):561-7.
-
1995: Vrouenraets B C; Klaase J M; Kroon B B; van Geel B N; Eggermont A M; Franklin H R
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.
Archives of surgery (Chicago, Ill. : 1960) 1995;130(1):43-7.
-
1995: Eggermont A M; Manusama E R; ten Hagen T L
Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program.
Journal of inflammation 1995;47(1-2):104-13.
-
1995: Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
The Journal of infusional chemotherapy 1995;5(2):73-81.
-
1995: Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
[Value of isolation-perfusion of the limbs in melanomas and sarcomas]
Annales de chirurgie 1995;49(1):9-12.
-
1995: Klaase J M; Kroon B B; Eggermont A M; van Geel A N; Schraffordt Koops H; Oldhoff J; Liénard D; Lejeune F J; Berkel R; Franklin H R
A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):58-63.
-
1994: Vrouenraets B C; Eggermont A M; Klaase J M; Van Geel B N; Van Dongen J A; Kroon B B
Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1994;20(6):681-5.
-
1994: Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
Journal of cellular biochemistry 1994;56(1):52-61.
-
1994: Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B; Gérain J; Rosenkaimer F; Schmitz P
Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.
Circulatory shock 1994;43(4):191-7.
-
1994: Klaase J M; Kroon B B; van Geel B N; Eggermont A M; Franklin H R; Hart G A
Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities.
American journal of surgery 1994;167(6):618-20.
-
1994: Renard N; Liénard D; Lespagnard L; Eggermont A; Heimann R; Lejeune F
Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha).
International journal of cancer. Journal international du cancer 1994;57(5):656-63.
-
1994: Klaase J M; Kroon B B; van Geel A N; van Wijk J; Franklin H R; Eggermont A M; Hart A A
Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion.
Journal of the American College of Surgeons 1994;178(6):564-72.
-
1994: Kapteijn B A; Klaase J M; van Geel A N; Eggermont A M; Kroon B B
Results of regional isolated perfusion for locally inoperable melanoma of the limbs.
Melanoma research 1994;4(2):135-8.
-
1994: Liénard D; Eggermont A M; Schraffordt Koops H; Kroon B B; Rosenkaimer F; Autier P; Lejeune F J
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
Melanoma research 1994;4 Suppl 1():21-6.
-
1994: Klaase J M; Kroon B B; van Geel A N; Eggermont A M; Franklin H R; van Dongen J A
Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?
Melanoma research 1994;4 Suppl 1():13-6.
-
1994: van Ravenswaay Claasen H H; Eggermont A M; Nooyen Y A; Warnaar S O; Fieuren G J
Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
Gynecologic oncology 1994;52(2):199-206.
-
1994: Kuppen P J; Basse P H; Goldfarb R H; Van De Velde C J; Fleuren G J; Eggermont A M
The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats.
International journal of cancer. Journal international du cancer 1994;56(4):574-9.
-
1994: Kuppen P J; Eggermont A M; Quak R B; Marinelli A; van de Velde C J; Fleuren G J
Soluble factors produced by macrophages/monocytes inhibit lymphokine-activated killer activity in rat splenocyte cultures.
Cancer immunology, immunotherapy : CII 1994;38(1):61-7.
-
1994: Klaase J M; Kroon B B; van Geel A N; Eggermont A M; Franklin H R; Hart A A
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
Surgery 1994;115(1):39-45.
-
1994: Smits K M; Kuppen P J; Eggermont A M; Tamatani T; Miyasaka M; Fleuren G J
Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells.
European journal of immunology 1994;24(1):171-5.
-
1994: Van de Vrie W; Jonker A M; Marquet R L; Eggermont A M
The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat.
Journal of cancer research and clinical oncology 1994;120(9):533-8.
-
1993: Van de Vrie W; Van der Heyden S A; Gheuens E E; Bijma A M; De Bruijn E A; Marquet R L; Van Oosterom A T; Eggermont A M
Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.
Cancer immunology, immunotherapy : CII 1993;37(5):337-42.
-
1993: Smits K M; Kuppen P J; Eggermont A M; Fleuren G J
Preincubation of tumor cells with the anti-(MHC) class I antibody OX18 enhances tumor cell lysis by interleukin-2-activated NK cells.
Transplantation proceedings 1993;25(5):2806-7.
-
1993: Smits K M; Kuppen P J; Lazeroms S P; Eggermont A M; Fleuren G J
Major histocompatibility complex class I expression and sensitivity to interleukin-2 activated NK cell-mediated lysis of adenovirus-transformed baby rat kidney cells.
Transplantation proceedings 1993;25(5):2804-5.
-
1993: Klaase J M; Kroon B B; van Geel A N; Eggermont A M; Franklin H R
Systemic leakage during isolated limb perfusion for melanoma.
The British journal of surgery 1993;80(9):1124-6.
-
1993: Beun G D; van de Velde C J; Fleuren G J; Eggermont A M
T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assays.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(1):11-5.
-
1993: Kuppen P J; Eggermont A M; Smits K M; van Eendenburg J D; Lazeroms S P; van de Velde C J; Fleuren G J
The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531.
Cancer immunology, immunotherapy : CII 1993;36(6):403-8.
-
1993: Klaase J M; Kroon B B; van Geel A N; Eggermont A M; Franklin H R; van Dongen J A
A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb.
Cancer 1993;71(10):2990-4.
-
1993: Kruit W H; Bolhuis R L; Goey S H; Jansen R L; Eggermont A M; Batchelor D; Schmitz P I; Stoter G
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):921-4.
-
1993: Vrouenraets B C; Kroon B B; Klaase J M; Van Geel B N; Eggermont A M; Franklin H R
Adjuvant regional isolated perfusion with melphalan for patients with Clark V melanoma of the extremities.
Journal of surgical oncology 1993;52(4):249-54.
-
1993: Vrouenraets B C; Kroon B B; Klaase J M; van Geel B N; Eggermont A M; Mooi W J; van Dongen J A
Regional isolated perfusion with melphalan for patients with subungual melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1993;19(1):37-42.
-
1993: Kroon B B; Klaase J M; van Geel B N; Eggermont A M; Franklin H R; van Dongen J A
Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):325-8.
-
1993: Van de Vrie W; Gheuens E E; Durante N M; De Bruijn E A; Marquet R L; Van Oosterom A T; Eggermont A M
In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.
Journal of cancer research and clinical oncology 1993;119(10):609-14.
-
1992: Klaase J M; Kroon B B; van Geel A N; Eggermont A M; Franklin H R; van Dongen J A
The role of regional isolated perfusion in the eradication of melanoma micrometastases in the inguinal nodes: a comparison between an iliac and femoral perfusion procedure.
Melanoma research 1992;2(5-6):407-10.
-
1992: Kuppen P J; Marinelli A; Camps J A; Pauwels E K; van de Velde C J; Fleuren G J; Eggermont A M
Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion.
International journal of cancer. Journal international du cancer 1992;52(2):266-70.
-
1992: Bolhuis R L; Lamers C H; Goey S H; Eggermont A M; Trimbos J B; Stoter G; Lanzavecchia A; di Re E; Miotti S; Raspagliesi F
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1992;7():78-81.
-
1992: Stoter G; Goey S H; Batchelor D; Eggermont A M; Lamers C; Gratama J W; Bolhuis R L
Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
Progress in clinical and biological research 1992;378():225-33.
-
1991: Kruit W H; Goey S H; Monson J R; Stahel R A; Calabresi F; Mertelsmann R; Holdener E E; Eggermont A M; Bolhuis R L; de Mulder P H
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.
British journal of haematology 1991;79 Suppl 1():84-6.
-
1991: Kuppen P J; Eggermont A M; Marinelli A; de Heer E; van de Velde C J; Fleuren G J
Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin.
Cancer immunology, immunotherapy : CII 1991;33(1):28-32.
-
1990: Bouwens L; Marinelli A; Kuppen P J; Eggermont A M; van de Velde C J; Wisse E
Electron microscopic observations on the accumulation of large granular lymphocytes (pit cells) and Kupffer cells in the liver of rats treated with continuous infusion of interleukin-2.
Hepatology (Baltimore, Md.) 1990;12(6):1365-70.
-
1990: Marinelli A; van de Velde C J; Kuppen P J; Franken H C; Souverijn J H; Eggermont A M
A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats.
British journal of cancer 1990;62(6):891-6.
-
1990: Stoter G; Goey S H; Eggermont A M; Slingerland R; Braakman E; Lamers C; Bolhuis R L
Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek.
Biotherapy (Dordrecht, Netherlands) 1990;2(3):261-5.
Sign-in to see more
